Table 2 Clinical Characteristics and Outcomes for the Prospective Cohort, Stratified by Lung Water Density
From: Quantification of lung water in heart failure using cardiovascular magnetic resonance imaging
CMR derived Lung Water Density Normal (≤ 20.8%) Wet (> 20.8%) | P value | ||
|---|---|---|---|
Patients, n | 151 | 52 | |
Male sex, n(%) | 86 (57) | 24 (46) | 0.18 |
Age at CMR, years | 67 ± 11 | 65 ± 12 | 0.18 |
BMI, kg/m2 | 29 ± 5 | 31 ± 7 | 0.002 |
Current smoker, n(%) | 21 (14) | 2 (4) | 0.048 |
Diabetes, n(%) | 48 (32) | 18 (35) | 0.71 |
Hypertension, n(%) | 118 (78) | 38 (73) | 0.46 |
CAD/MI, n(%) | 57 (38) | 17 (33) | 0.51 |
Atrial Fibrillation, n(%) | 51 (34) | 17 (33) | 0.89 |
COPD, n(%) | 20 (13) | 12 (23) | 0.09 |
Beta Blocker use, n(%) | 97 (64) | 39 (75) | 0.15 |
ACEi or ARB use, n(%) | 123 (81) | 45 (87) | 0.40 |
Loop diuretic use, n(%) | 61 (40) | 31 (60) | 0.016 |
Spironolactone use, n(%) | 27 (18) | 10 (19) | 0.83 |
History of heart failure | 83 (55) | 38 (73) | 0.022 |
NYHA, n(%) | 0.002 | ||
Class I | 25 (30) | 3 (8) | |
Class II | 43 (52) | 17 (45) | |
Class III | 15 (18) | 17 (45) | |
Class IV | 0 (0) | 1 (3) | |
Systolic BP, mmHg | 133 ± 19 | 132 ± 22 | 0.75 |
Elevated JVP, n(%) | 25 (17) | 19 (37) | 0.003 |
Rales, n(%) | 5 (3) | 7 (13) | 0.007 |
BNP, pg/ml | 111 ± 122 | 282 ± 330 | < 0.001 |
Creatinine, umol/L | 91 ± 32 | 96 ± 39 | 0.38 |
LVEF, %, by MRI | 54 ± 13 | 48 ± 19 | 0.013 |
Outcomes at 1 year, n(%) | |||
Death | 1 (1) | 3 (6) | 0.022 |
Death, CV hosp or CV ED visit | 19 (13) | 15 (29) | 0.007 |